Where are we in diabetic nephropathy: MicroRNAs and biomarkers

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 80-86

  McClelland, Aaron ^a   Hagiwara, Shinji ^a   Kantharidis, Phillip ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

biomarkers, fibrosis, microRNA, TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; COLLAGEN TYPE 2; FIBRONECTIN; GELATINASE B; MICRORNA; MICRORNA 192; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 29; MICRORNA 29A; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2; UVOMORULIN; VIMENTIN;

DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; FIBROBLAST; FIBROGENESIS; GENE OVEREXPRESSION; HUMAN; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY HYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; URETER OBSTRUCTION; URINE SEDIMENT;

ANIMALS; DIABETIC NEPHROPATHIES; GENETIC MARKERS; GENETIC THERAPY; HUMANS; KIDNEY; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890547522     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437612.50040.ae     Document Type: Review

References (44)

1. Li JH, Huang XR, Zhu HJ, et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: Implications for diabetic renal and vascular disease. FASEB J 2004; 18:176-178.
2. Li JH, Wang W, Huang XR, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGEERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164:1389-1397.
3. Meng XM, Huang XR, Chung AC, et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010; 21:1477-1487.
4. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981.
5. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: A mobile purveyor of immune privilege. Immunol Rev 2006; 213:213-227.
6. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601.
7. Winbanks CE, Wang B, Beyer C, et al. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 2011; 286:13805-13814.
8. Duursma AM, Kedde M, Schrier M, et al. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14:872-877.
9. Kim DH, Saetrom P, Snove O Jr, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 2008; 105:16230-16235.
10. Younger ST, Corey DR. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res 2011; 39:5682-5691.
11. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21:1247-1253.
12. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res 2012; 347:103-116.
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420-1428.
14. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894-907.
15. Ogihara T. 14-3-3 Protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 1997; 272:25267-25274.
16. Jiang L, Qiu W, Zhou Y, et al. A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-beta1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis. Kidney Int 2013; 84:285-296. This study demostrated the induction of UCP2 after TGF-b-mediated downregulation of miR-30e.
17. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
18. Hagiwara S, Kantharidis P, Cooper ME. microRNA as biomarkers and regulator of cardiovascular development and disease. Curr Pharm Des 2013. [Epub ahead of print]
19. Chen NX, Kiattisunthorn K, O'Neill KD, et al. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PloS One 2013; 8:e64558. This study identified elevated mir-145 and miR-155 levels in blood in patients with CKD.
20. Jeppesen PL, Christensen GL, Schneider M, et al. Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol 2011; 164:394-404.
21. Jin W, Reddy MA, Chen Z, et al. Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem 2012; 287:15672-15683. This is the study showing that miR-132 and miR-212 are induced by AngII in VSMCs
22. Eskildsen TV, Jeppesen PL, Schneider M, et al. Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci 2013; 14:11190-11207. This study shows that miR-132 and miR-212 are significantly increased in tissues associated with blood pressure control such as kidney and heart by AngII, and reduced in ARB-treated patients.
23. DiStefano JK. Identification of novel genetic markers and improved treatment options for diabetic kidney disease. Biomarkers Med 2010; 4:739-741.
24. Thomas MC, Groop PH, Tryggvason K. Towards understanding the inherited susceptibility for nephropathy in diabetes. Curr Opin Nephrol Hypertens 2012; 21:195-202.
25. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107:810-817.
26. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovas Res 2012; 93:583-593.
27. Aggio RB, Ruggiero K, Villas-Boas SG. Pathway activity profiling (PAPi): From the metabolite profile to the metabolic pathway activity. Bioinformatics 2010; 26:2969-2976.
28. Argyropoulos C, Wang K, McClarty S, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PloS One 2013; 8:e54662.
29. Wang N, Zhou Y, Jiang L, et al. Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PloS One 2012; 7:e51140.
30. Szeto CC, Ching-Ha KB, Ka-Bik L, et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers 2012; 33:137-144.
31. Wang G, Kwan BC, Lai FM, et al. Urinary miR-21, miR-29, and miR-93: Novel biomarkers of fibrosis. Am J Nephrol 2012; 36:412-428.
32. Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PloS One 2013; 8:e58014.
33. Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications. J Cardiovasc Translat Res 2012; 5:413-422.
34. Denby L, Ramdas V, McBride MW, et al. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol 2011; 179:661-672.
35. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22:1668-1681.
36. Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PloS One 2011; 6:e16979.
37. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456:980-984.
38. Raitoharju E, Lyytikainen LP, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011; 219:211-217.
39. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: The microRNA perspective. Diabetes 2011; 60:1832-1837.
40. Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Visual Sci 2011; 52:4402-4409.
41. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105:13027-13032.
42. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol 2011; 31:3182-3194.
43. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13:239-250.
44. Yang Y, Xiao L, Li J, et al. Urine miRNAs: Potential biomarkers for monitoring progression of early stages of diabetic nephropathy. Med Hypotheses 2013; 81:274-278.